Thank You Government Employees
Cancer Research And Biostatistics (CRAB) would like to thank all of the employees of King County government and the federal and military personnel who support our work through employee giving programs in 2014.
CRAB is focused on people, people you may know – people with underfunded and under-researched cancers, the ones we can’t yet routinely cure, such as myeloma, pancreatic and lung cancers.
Today, these three cancers along take more than 209,000 lives a year in the United States.
Thank you for helping us reduce these numbers!
In the last year along, CRAB helped bring new choices to patients – one of these could be the one that makes a difference.
With your generous contributions, we can build upon these successes to provide more treatment options to event more cancer patients, sooner.
Thank you for your support and we look forward to partnering with you again in 2015!
CRAB Joins the #GivingTuesday Movement
We had a day to give thanks and two days for getting great deals.
Now, we have a a day dedicated to giving back and supporting our favorite charities - #GivingTuesday, a day of online giving.
Cancer Research And Biostatistics (CRAB) is proud to join this growing movement of generosity on December 2.
CRAB is focused on people, people you may know - people with underfunded and under-researched cancers, the ones we can’t yet routinely cure, such as myeloma, pancreatic and lung cancers. Today, these three cancers alone take more than 209,000 lives a year in the U.S.
We need to reduce these numbers – you can help.
In the last year alone, CRAB helped bring new choices to patients– one of these could be the one that makes a difference. With your contributions, we can build upon these successes to provide more treatment options to even more cancer patients, sooner.
Thank you for Supporting CRAB on #GivingTuesday!
CRAB Appoints Dr. Antje Hoering as New CEO
Seattle, WA. November 3rd, 2014. Cancer Research And Biostatistics (CRAB) announced today that its Board of Directors named Dr. Antje Hoering as the organization’s next Chief Executive Officer, effective January 1, 2015. Dr. Hoering brings distinguished academic and scientific achievements, executive leadership and over 15 years of experience to the role. Dr. Hoering, currently the Chief Scientific Officer at CRAB, presently serves as the lead statistician for the SWOG Myeloma Committee and is an active member of the Myeloma Steering Committee for the National Clinical Trials Network. Dr. Hoering also serves as the Director of the Biostatistics Core for a SPORE grant funded through the Sarcoma Alliance for Research Through Collaboration, and is the Co-Director of the Biostatistics Core for a Program Project through the Myeloma Institute for Research and Therapy.
Dr. John Crowley, CRAB’s current CEO says “Antje brings a unique and comprehensive background in applied and methodological research in biostatistics, encompassing areas such as the design and analysis of oncology clinical trials, as well as the analysis of a wide variety of correlative data. I have worked with Antje for 10 years at CRAB, and am proud to hand over the leadership reins to her.”
Dr. Antje Hoering comments, “I am honored and humbled to be taking over the reins from our founder, John Crowley. This is a very exciting time for oncology clinical trials and CRAB. There have been great advances in the treatment of cancer over the last few years and it is now more important than ever to definitively test the efficacy and tolerability of these treatments in soundly-designed clinical trials. CRAB offers an integrated, state-of-the-art infrastructure including sophisticated statistics, secure electronic data capture as well as experienced data management to lead such trials.”
Hoering will succeed John Crowley, CRAB’s founder and CEO since 1997, who will stay on to focus on research and project activities and will continue to serve as CRAB’s Chairman of the Board.
Dr. Hoering will be based at CRAB’s headquarters in Seattle, WA.
About Cancer Research And Biostatistics (CRAB)
CRAB is a non-profit organization whose mission is to help conquer cancer and other diseases through the application of biostatistical principles and innovative data management methods. CRAB provides a complete suite of cancer clinical trial services including the design of therapeutic and prevention trials, customized electronic data capture platforms, and data management and statistical services from clinical protocol design to final data analysis and presentation.
For more information, visit www.crab.org.
Media Contact for CRAB
Vice President, Chief Business Officer
Shop at Fred Meyer and raise money for CRAB
Through its Community Rewards program, Fred Meyer is giving away $625,000 to nonprofits each quarter in 2014.
Enroll online and link your Rewards Card to CRAB by visiting www.fredmeyer.com/communityrewards. Don't worry; you'll still receive all Rewards Card perks. You'll just also raise money for CRAB every time you shop and use your Rewards Card!
So be sure to link your rewards card to CRAB, and the next time you shop at Fred Meyer, know you are helping support cancer research.
CRAB Presents at CANSSI in Toronto
Dr. Antje Hoering presented at the Workshop on Statistical Issues in Biomarker and Drug Co-development. The workshop was held in Toronto and sponsored by CANSSI, the Canadian Statistical Sciences Institute.
The 1.5-day workshop on biomarker and drug co-development focused on education of researchers about emerging developments in statistical designs and analyses for clinical trials and translational research, as well as to identify open statistical problems for which attendees will consider organizing research proposals. International experts provided an introduction to biomarker data and an overview of current design, analysis, and reporting principles with issues for research. Workshop participants solidified their knowledge about the current state of the field(s); networked, identified knowledge gaps and to proposed research initiatives that will be the focus of a full grant application which will globally enhance and expedite biomarker research.
For more details about the workshop please visit its website at http://www.fields.utoronto.ca/programs/scientific/14-15/biomarker/.
PurpleStride 2014: Pasta and Participation
Members of CRABCares, CRAB colleagues and their familes joined together over the past week, at CRAB and at Magnusson Park in Seattle's Sand Point neighborhood, to support CRABCares' participation in PurpleStride 2014. Much support and merriment was shared to benefit pancreatic cancer research.
The CRABCares pasta potluck on October 30th featured the cooking talents of CRAB employees who dazzled diners with baked ziti, spaghetti and quinoa noodles, among other dishes. Raffle prizes were won and smiles were spotted. On November 2nd colleagues gathered under CRAB's canopy at PurpleStride 2014 to share cocoa, doughnuts, run/walk strategies and cheers.
Responsibility for Pancreatic Cancer Research Team Moves to Seattle Non-Profit Institution
Seattle, WA. September 10, 2014 Seattle’s own Cancer Research And Biostatistics (CRAB), and Translational Drug Development (TD2) in Scottsdale, would like to jointly announce CRAB’s assumption of responsibility for the PCRT, a world-renowned consortium comprised of a team of pancreatic cancer experts committed to improve treatment outcomes for patients with this deadly cancer.
Founded by leaders in pancreatic cancer clinical research, the PCRT is a consortium of more than 40 clinics and leading research institutions worldwide and serves as a premiere resource for the latest clinical trials. In addition, the PCRT provides a valuable collaborator for biotech and pharmaceutical companies looking to develop new agents for patients with pancreas cancer. This network provides the world's most coordinated effort dedicated to rapidly translating research discoveries into new treatments and care.
“Dr. John Crowley and CRAB have a distinguished record in clinical trials excellence. The PCRT has been working with the CRAB team for over ten years. It is gratifying to see CRAB take this growing group of devoted investigators to the next level”, said Daniel D. Von Hoff, M.D., FACP, Physician in Chief, Distinguished Professor, Translational Genomics Research Institute (TGen), Chief Scientific Officer, Scottsdale Healthcare, and one of the Founders and current Board member of PCRT.
You may access the full press release at this link: http://www.prweb.com/releases/2014/9/prweb12163611.htm